See more : BizRocket.com, Inc. (BZRT) Income Statement Analysis – Financial Results
Complete financial analysis of 2seventy bio, Inc. (TSVT) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of 2seventy bio, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- YTO Express (International) Holdings Limited (6123.HK) Income Statement Analysis – Financial Results
- PT Ketrosden Triasmitra (KETR.JK) Income Statement Analysis – Financial Results
- Betmakers Technology Group Ltd (BET.AX) Income Statement Analysis – Financial Results
- ZTE Corporation (ZTCOY) Income Statement Analysis – Financial Results
- Shree Bhavya Fabrics Limited (SBFL.BO) Income Statement Analysis – Financial Results
2seventy bio, Inc. (TSVT)
About 2seventy bio, Inc.
2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. Its products pipeline includes idecabtagene vicleucel; ide-cel or Abecma and bb21217; and CAR-T cell product candidates for the treatment of multiple myeloma. 2seventy bio, Inc. has a collaboration arrangement with Bristol-Myers Squibb Company. The company was incorporated in 2021 and is headquartered in Cambridge, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 100.39M | 91.50M | 54.52M | 248.12M | 44.30M | 54.58M |
| Cost of Revenue | 16.92M | 26.22M | 12.59M | 5.40M | 2.98M | 885.00K |
| Gross Profit | 83.47M | 65.28M | 41.93M | 242.73M | 41.32M | 53.69M |
| Gross Profit Ratio | 83.15% | 71.34% | 76.91% | 97.83% | 93.28% | 98.38% |
| Research & Development | 230.76M | 248.74M | 261.94M | 296.47M | 297.65M | 200.49M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 69.41M | 79.45M | 93.51M | 90.90M | 81.65M | 53.63M |
| Other Expenses | 20.91M | 6.06M | 21.65M | 18.06M | 20.13M | 19.16M |
| Operating Expenses | 321.08M | 328.19M | 355.44M | 387.36M | 379.29M | 254.12M |
| Cost & Expenses | 317.09M | 354.40M | 368.03M | 392.76M | 382.27M | 255.01M |
| Interest Income | 12.41M | 2.93M | 88.00K | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 15.49M |
| Depreciation & Amortization | 10.29M | 11.53M | 16.40M | 13.19M | 12.59M | 13.35M |
| EBITDA | -206.42M | -251.38M | -297.16M | -131.45M | -329.19M | -187.08M |
| EBITDA Ratio | -205.62% | -274.49% | -574.21% | -45.70% | -728.37% | -307.66% |
| Operating Income | -216.70M | -262.91M | -313.51M | -144.64M | -337.97M | -203.43M |
| Operating Income Ratio | -215.87% | -287.34% | -575.01% | -58.29% | -762.99% | -372.72% |
| Total Other Income/Expenses | -867.00K | 8.76M | 21.30M | 24.52M | 17.38M | 3.68M |
| Income Before Tax | -217.57M | -254.15M | -292.21M | -120.11M | -320.59M | -199.75M |
| Income Before Tax Ratio | -216.73% | -277.77% | -535.95% | -48.41% | -723.75% | -365.98% |
| Income Tax Expense | 0.00 | -8.99K | -16.00M | 18.06M | 2.75M | 19.16M |
| Net Income | -217.57M | -254.14M | -276.21M | -138.17M | -323.34M | -199.75M |
| Net Income Ratio | -216.73% | -277.77% | -506.61% | -55.69% | -729.96% | -365.98% |
| EPS | -4.42 | -7.13 | -11.71 | -5.93 | -13.88 | -8.58 |
| EPS Diluted | -4.42 | -7.13 | -11.71 | -5.93 | -13.88 | -8.58 |
| Weighted Avg Shares Out | 49.28M | 35.64M | 23.59M | 23.29M | 23.29M | 23.29M |
| Weighted Avg Shares Out (Dil) | 49.28M | 35.64M | 23.59M | 23.29M | 23.29M | 23.29M |
2seventy bio to Report Second Quarter 2024 Financial Results on August 7, 2024
CAMBRIDGE, Mass.--(BUSINESS WIRE)--2seventy bio, Inc. (Nasdaq: TSVT) will announce its second quarter 2024 financial results on Wednesday, August 7, 2024. A conference call and webcast will be held at 8:00 a.m. ET. Participants can access the conference call live via...
2seventy bio's Abecma: Compelling Investment In Multiple Myeloma Despite Competition
2seventy bio, Inc. focuses on Abecma, an FDA-approved CAR T cell therapy for multiple myeloma. TSVT's strategic realignment includes selling non-core assets to Regeneron and Novo Nordisk. Abecma shows favorable clinical data but faces strong competition from Carvykti.
3 Hidden Stock Gems That Wall Street Is Overlooking
No matter your investing style, we all hope to find overlooked stock gems. These are where the biggest gains are made.
2seventy bio Announces Sale of Hemophilia A Candidate and MegaTAL In Vivo Gene Editing Technology to Novo Nordisk for up to $40 million
CAMBRIDGE, Mass.--(BUSINESS WIRE)--2seventy bio, Inc. (Nasdaq: TSVT), announced today the completion of an asset purchase agreement (“APA”) by Novo Nordisk. Under the terms of the APA, Novo Nordisk has acquired the Hemophilia A program and rights to 2seventy's in vivo...
2seventy bio to Participate in Upcoming Investor Conferences
CAMBRIDGE, Mass.--(BUSINESS WIRE)--2seventy bio, Inc. (Nasdaq: TSVT) announced today that members of the management team will present at the following upcoming investor conferences: TD Cowen 5th Annual Oncology Innovation Summit: Insights for ASCO & EHA in a virtual fireside chat...
2seventy bio, Inc. (TSVT) Q1 2024 Earnings Call Transcript
2seventy bio, Inc. (NASDAQ:TSVT ) Q1 2024 Earnings Conference Call May 8, 2024 8:00 AM ET Company Participants Jenn Snyder - Senior Vice President, Corporate Affairs Chip Baird - Chief Executive Officer Vicki Eatwell - Chief Financial Officer Anna Truppel-Hartmann...
2seventy bio, Inc. (TSVT) Reports Q1 Loss, Tops Revenue Estimates
2seventy bio, Inc. (TSVT) came out with a quarterly loss of $0.81 per share versus the Zacks Consensus Estimate of a loss of $0.72. This compares to loss of $1.08 per share a year ago.
2seventy bio to Report First Quarter 2024 Financial Results on May 8, 2024
CAMBRIDGE, Mass.--(BUSINESS WIRE)--2seventy bio, Inc. (Nasdaq: TSVT) will announce its first quarter 2024 financial results on Wednesday, May 8, 2024. A conference call and webcast will be held at 8:00 a.m. ET. Participants can access the conference call live via...
2seventy bio, Inc. (TSVT) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
2seventy bio, Inc. (TSVT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
2seventy bio (TSVT) Rises More Than 50% in 3 Months: Here's Why
The FDA's recent nod to 2seventy bio's (TSVT) Abecma in earlier lines of treatment for relapsed/refractory multiple myeloma is a positive. Also, the R&D asset divestiture to Regeneron is saving costs.
Source: https://incomestatements.info
Category: Stock Reports